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Poster Session I S255findings included lytic lesions, pathological fractures or compression
fractures of vertebral bodies that were not seen well by the skeletal
survey. However, there were no significant differences in the median
PFS or OS between the two patient groups. There were total of 9 pa-
tients that had no bony lesions in either the survey or the CT scan
and their PFS and OS were not different either. We conclude that
CT scan of the skeleton is more sensitive in defining existing bony
lesions in MM patients at diagnosis, although these extra findings
may not have any impact on the PFS or OS of patients undergoing
SCT. The CT scan findings may have implications to palliative
and supportive care treatments for these patients.278
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Introduction: A study was conducted to compare a new powered
bone marrow sampling device to traditional manual bone marrow
sampling devices. The specific objectives of the study were to exam-
ine the number of passes required to obtain a satisfactory bone mar-
row core sample and measure the length of samples obtained from
each pull, using each device-type; and compare the results.
Methods: All patients had been diagnosed with multiple myeloma
and had undergone previous bone marrow biopsy procedures. Clini-
cians were already well experienced using the manual device, but had
only limited experiencewith the powered device. Following consent-
ing procedures and local anesthetic administration, 2 biopsy proce-
dures were performed unilaterally on each patient; one using the
traditional manual device and one using the powered device. The
manual device was a Jamshidi 11 gauge  4 inch needle (Cardinal
Health, Dublin, OH). The OnControl powered device included an
11 gauge, 102cm needleset (OnControl, Vidacare Corporation, Sha-
vano Park, TX). The device-type for the first procedure was alter-
nated from one patient to the next. Data collected included the
core specimen length obtained for analysis, and the number of pulls
required for a satisfactory specimen—defined by pathologists as
a core sample at least 1.0cm in length. An ‘‘ideal’’ specimen was de-
fined by pathologists as one with a length of $ 1.7cm. Pathology
graded specimens as Satisfactory, Unsatisfactory, or Limited. For
study purposes, up to 3 passes were allowed to obtain core speci-
mens. Results were compared between device-types and pull se-
quence. Data analysis, including descriptive statistics, t-tests, and
Chi-square analysis was performed using SPSS Statistics 19.0 soft-
ware (SPSS, Inc. Chicago, IL), with an alpha level of 0.05.
Results: Over a 30-day period, double biopsy procedures were per-
formed for 20 patients by 4 medical clinicians (1 nurse and 3 medical
assistants). See Table for specific results.Table 1. Study Results
Results by Device-Type Manual
Mean number of passes for procedure 1.95 ± 0.95
Core sample obtained on first pass 55%
Mean biopsy core length (mm) 1.11 ± 0.59
Ideal length core sample obtained
on first pass
20%
Pathology graded core sample
satisfactory or limited
85%
Results by Pull Sequence 1st
Mean number of passes for procedure 1.55 ± 0.89
Core sample obtained on first pass 65%
Mean biopsy core length (mm) 1.67 ± 0.57
Ideal length core sample obtained
on first pass
30%
Pathology graded core sample
satisfactory or limited
80%
†indicates statistical significanceConclusions: Study results suggest that, for multiple myeloma pa-
tients, the Powered bone marrow biopsy device may be preferable
to traditional Manual devices. This is due to the ability of operators
to consistently obtain ideal or adequate core biopsy specimens with
only one pass. Fewer passes means faster procedures and may result
in a reduction in pain to the patient, as well as less fatigue to the
clinician/operator.279
SUCCESSFUL AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWING A
COMBINED HEART-KIDNEY TRANSPLANTATION FOR AL AMYLOIDOSIS
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Background: Simultaneous cardiac and renal involvement is associ-
ated with a particularly poor prognosis in patients with AL amyloid-
osis. High-dose melphalan followed by autologous stem cell
transplantation (ASCT) offers the best chance for long-term survival
in patients with AL amyloidosis. Eligibility criteria for ASCT differ
between hematologic centers, because this treatment is associated
with high levels of mortality, which are increased by cardiac and/or
renal involvement. However, successful ASCT was reported after
cardiac and renal transplantation.
CaseReport:We report a case of a successful ASCT following com-
bined heart and kidney transplantation in a patient with systemic AL
amyloidosis. The recipient was a 61-year-old man with end-stage re-
nal failure associated with restrictive cardiomyopathy secondary to
AL amyloidosis. On presentation, cardiac biopsy showed cardiac am-
yloid involving the intramural arteries and interstitium and kidney
biopsy showed renal amyoid with lambda light chain deposition. Ini-
tial bone marrow biopsy showed a 40-50% cellular marrow with 4%
plasma cells and serum lambda light chains were elevated at 37.5 mg/
ml (5.7-26.3). One year after presentation, he underwent a successful
combined heart and kidney transplant. His post-transplant course
has been unremarkable except for ureteral leak that required surgical
revision. Immune suppression was maintained with tacrolimus and
mycophenolate mofetil. Four months after, he received 100 mg/
m2 melphalan on D-3 followed by ASCT. The infused stem cells
dose was 7.33  106/kg (which was half of what was collected). My-
cophenolate dose was reduced to allow engrafment and patient was
started on growth factors byD17. Immediate post-transplant course
was complicated by neutropenic fever secondary to streptococcus
viridans bacetermia which was successfully treated with. Patient
had successfully engrafted by D112 and was discharged from the
hospital by D117. One month after discharge of the hospital, he
continues to do well and didn’t require any blood product support.
Discussion: ASCT following combined heart and kidney transplant
is safe and feasible.We await to observe long-term outcomes though.Powered p-value
1.05 ± 0.22 <0.001†
97% <0.001†
1.60 ± 0.36 0.003†
55% 0.048†
85% 0.889
2nd p-value
1.45 ± 0.76 0.704
70% 0.710
1.77 ± 0.35 0.507
45% 0.257
90% 0.637
